Form 4: Coya Therapeutics Director Acquires Stock Options

Anabella Villalobos, a director at Coya Therapeutics, acquired 5,000 stock options on January 1, 2025.

Summary

• Anabella Villalobos, a director of Coya Therapeutics, acquired 5,000 stock options on January 1, 2025.
• The options have an exercise price of $5.73 per share.
• The options vest 100% on the first anniversary of the grant date, which is January 1, 2026.
• The options expire on January 1, 2035.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction, which is neither particularly positive nor negative. It is a standard part of executive compensation.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.

Industry Context

This is a standard transaction for a director of a public company, often used as part of compensation packages to align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in publicly traded companies.
• The vesting schedule of 100% after one year is a typical vesting period for stock options.
• The exercise price of $5.73 is specific to Coya Therapeutics and would need to be compared to other similar companies to assess its relative value.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates

Keywords

stock options, director, Coya Therapeutics, equity, insider trading, beneficial ownership